INTRODUCTION AND OBJECTIVES: Collagenase clostridium histolyticum (CCH)is the only licensed product for the treatment of Peyronie's disease (PD). The clinical safety and efficacy of CCH in PD was shown in two large clinical trials; IMPRESS I & II. The aim of this study is to evaluate the efficacy and safety of CCH in the treatment of PD using a new modified treatment protocol which aims at reducing the number of injections needed and reducing patient visits, thus reducing the cost and duration of treatment.
METHODS: A prospective study of 50 patients with PD who are having treatment with CCH at a single centre using a new modified protocol. Patients with active disease, complete plaque calcification or ventral curvature were excluded. The angle of curvature assessment after an intra-cavernosal injection of PGE1, IIEF and Peyronie's disease questionnaire (PDQ) were performed at baseline and at week 12. The global assessment of PD questionnaire was performed at week 12. Under a penile block of 10ml of lignocaine 1%, a total of 3 intra-lesional injections of CCH (0.9mg) were given at 4 weekly intervals using a new modified injection technique. CCH was injected in the plaque along 3 lines separated by 2mm at the apex of the curvature with the penis in the flaccid state. Six patients requested an additional 3 injections to have a total of 6 injections. In between injections patients used a combination of home modelling, stretching and a vacuum device on a daily basis in order to mechanically stretch the plaque. Investigator modelling was not performed.
RESULTS: So far 46 patients have completed treatment; all had 3 injections. At baseline, the mean penile curvature was 53.8 (30 -90 ). Overall, 44 patients (95.6%) had an improvement in curvature with a mean value of 17.08 (0 -40 ) or 30.8% from baseline (0-57%) after 3 injections. The end mean curvature for all patients after 3 injections was 37 (12 -75 ; p 0.001). There was a statistically significant improvement in each of the IIEF questionnaire domains, all 3 PDQ domains and the global assessment of PD questionnaire. The 6 patients who had 3 more injections continued to have additional curvature improvement, mean 19.8 (0 -40 ). CCH was well tolerated by all patients with only mild and transient local side effects. The results of this study with only 3 CCH injections are comparable to those of the clinical trials using 8 CCH injections. With the new protocol, only 4 patient visits are needed including assessments versus 14 visits as per trial protocol.
CONCLUSIONS: The new shortened protocol for CCH in PD is safe, effective and cost efficient. INTRODUCTION AND OBJECTIVES: CCH is the only FDA approved medical treatment for peyronie's disease. Variable protocols exist regarding pretreatment evaluation, patient selection, procedural therapy and post treatment protocols. The objective of this study was to identify practice patterns of SMSNA members with respect to CCH treatment to better standardize protocols for safety and efficacy.
METHODS: A 10 question survey was sent via survey monkey to SMSNA membership in November 2016. Questions solicited frequency of administration, use of formal peyronie's disease questionnaires (PDQ), use of other intralesional therapies, preprocedure objective measurements, remeasuring frequency, post procedure local wound care, use of post op modeling and stretch options. Off label use and in office and home modeling protocols were queried as well.
RESULTS: 85% of respondents typically inject at least 10 CCH injections/per month. Refer to table 1 for questions Off label use of CCH included ventral (17%), pain only (9.4%), curvature of less than 6 months duration (59%), unstable active disease (28%) and conformational architectural changes (78%). 45.8% will do only in office modeling once and all subsequent is done at home, while 30.5% do in office modeling and home modeling with each cycle.
CONCLUSIONS: Most SMSNA members that took the survey used intralesional CCH frequently. Most do NOT use a Peyronie's PDQ prior to therapy and most measure curvature prior to therapy with intracavernosal injection, but not after each cycle. 62% offer other intralesional therapy in their practice. As November 2016, most did not use a stretching device or vacuum erection device in the modeling process. Most commonly, in office modeling is usually done just ONCE in the office. Many SMSNA members use CCH for off label indications such as active disease, prior to 6 month duration and ventral curvature. This data offers the information about the variety of protocols utilized by active CCH users. METHODS: Between June 2014 and September 2016, we evaluated and treated 52 patients with stable PD Curvature (predominately dorsal with palpable plaque) Our protocol consists of 3 month cycles it begins with a one CCH injections for the first 2 weeks giving a total dose of 0,58 mg, following by modeling under local anesthesia during the initial month and two months of "Triple Therapy" -tadalafil 5mg daily, pentoxifiline 400mg twice a day and 6-8 hours of penile traction therapy.
Source of Funding: None
RESULTS: The cohort mean age was 56 (43-71) years with a mean curvature of 54 (30-90) degrees. During our mean follow up of 10 months, we noted significant clinical improvement in in PDQ bother scores from 7.5 to 4.2. Likewise there was PDQ symptoms improvement from 11.5 to 7.8. There was a median of 2 cycles (1-4) per patient and 75% had positive responses after 2 cycles. The mean curvature reduction or degree improvement per cycle was 14 grades (11-18). Five patients (9%) have required surgery for complete PD resolution. All side e756 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
